- the management of someone or something; "the handling of prisoners"; "the treatment of water sewage"; "the right to equal treatment in the criminal justice system" (同)handling
- care provided to improve a situation (especially medical procedures or applications that are intended to relieve illness or injury) (同)intervention
- a manner of dealing with something artistically; "his treatment of space borrows from Italian architecture"
- a stopping; "a cessation of the thunder" (同)surcease
- 〈U〉(人・物の)『取り扱い』,扱い方《+of+名》 / 〈U〉治療;〈C〉(…に対する)治療法《+for+名》
- 《所有・所属》…『の』,…のものである,…に属する・《材料・要素》…『でできた』,から成る・《部分》…『の』[『中の』] ・《数量・単位・種類を表す名詞に付いて》…の・《原因・動機》…『で』,のために(because of) ・《主格関係》…『の』,による,によって・《目的格関係》…『を』,の・《同格関係》…『という』・《関係・関連》…『についての』[『の』],の点で・《抽象名詞などと共に》…の[性質をもつ] ・《『It is』+『形』+『of』+『名』+『to』 doの形で,ofの後の名詞を意味上の主語として》・《分離》…『から』・《起原・出所》…『から』[『の』](out of) ・《『名』+『of』+『a』(『an』)+『名』の形で》…のような・《『名』+『of』+『mine』(『yours, his』など独立所有格)の形で》…の…・《時》(1)《副詞句を作って》…に《形容詞句を作って》…の・《時刻》《米》…前(to,《米》before)
- OLD French古[代]フランス語
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience.
- Park YW, Yeom KB, Choi JW, Kim DY, Shin H, Kim KH.Author information Department of Dermatology, Seoul National University College of Medicine.AbstractBackground: Propranolol has recently become a successful first-line therapy in the treatment of infantile hemangiomas (IHs). Objective:To evaluate and analyze the authors' experience of propranolol treatment for IHs. Methods: A retrospective, observational study was conducted. Medical records were reviewed. To evaluate the outcome of treatment, serial digital photographs using a visual analog scale were compared. Results:Eighty-three patients with a mean age of 5.35 ± 5.15 months had 107 IHs treated by oral propranolol at a dose of 2 mg/kg/day. The mean percent improvement in the size and extent were 14.3% at 1 week, 45.4% at 9 weeks, 69.1% at 21 weeks and 83.8% at 53 weeks after beginning propranolol treatment. Eight patients (9.6%) reported mild side effects including hypoglycemia (n = 4), hypotension without associated symptoms (n = 2), bradycardia (n = 1) and somnolence (n = 1). Regrowth of IH after cessation of propranolol was reported in 18 patients (21.7%). There is no significant predictor of response to treatment and regrowth after cessation of treatment. Conclusions: Propranolol was highly effective and safe in the treatment of IHs. Effect of propranolol treatment started rapidly within 1 week, and was very promising regardless of patients' and lesions' characteristics. Based on the authors' observation, they suggest that treatment should be continued several months after the proliferative phase is considered to stop clinically.
- The Journal of dermatological treatment.J Dermatolog Treat.2014 Oct;25(5):391-5. doi: 10.3109/09546634.2012.761667. Epub 2013 Feb 24.
- Background: Propranolol has recently become a successful first-line therapy in the treatment of infantile hemangiomas (IHs). Objective:To evaluate and analyze the authors' experience of propranolol treatment for IHs. Methods: A retrospective, observational study was conducted. Medical records were r
- PMID 23273264
- Integrating smoking cessation into substance use disorder treatment for military veterans: Measurement and treatment engagement efforts.
- Shealy SE, Winn JL.Author information James A. Haley Veterans' Hospital, United States. Electronic address: Suzanne.email@example.com.AbstractMilitary personnel and veterans smoke at higher rates than the general population, compromising physical performance readiness and health (Committee on Smoking Cessation in Military and Veteran Populations & Institute of Medicine, 2009). While efforts are being made within both the Department of Defense and the Veterans' Administration (VA) hospitals to prevent onset, change the smoking culture, and promote smoking cessation; smoking rates are increasing among combat deployed service members, and smoking rates are particularly high among veterans with mental health and other substance use disorders (McFall, 2006). Recent research supports making smoking cessation widely available and integrated with other forms of care (Gierisch et al., 2012; McFall et al., 2010). This paper describes the efforts of one VA substance use disorder (SUD) treatment program to integrate smoking cessation in routine care, including assessment of tobacco use and motivation and intention to quit via the proposed Nic-BAM assessment. Our team was 100% successful in incorporating the Nic-BAM into our regular assessment of treatment program participants. This suggests that staff members are amenable to assessing for tobacco addiction alongside other substance addictions. Although smoking did not decrease according to the Nic-BAM, an increase in the use of nicotine-replacement products suggests that participants are willing to initiate a quit attempt during SUD treatment. The availability of new evidence-based approaches for integration of tobacco cessation with mental health and SUD treatment may help to enhance programmatic efforts. Environmental changes are needed to fully incorporate tobacco recovery into SUD programming, and additional resources may include peer support specialists.
- Addictive behaviors.Addict Behav.2014 Feb;39(2):439-44. doi: 10.1016/j.addbeh.2013.07.014. Epub 2013 Aug 17.
- Military personnel and veterans smoke at higher rates than the general population, compromising physical performance readiness and health (Committee on Smoking Cessation in Military and Veteran Populations & Institute of Medicine, 2009). While efforts are being made within both the Department of
- PMID 24094921
- Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
- Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de Braud F, Garassino MC.Author information Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.AbstractThe treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. In the last few years, intensive investigational efforts in anticancer therapy have led to the registration of new active chemotherapeutic agents, combination regimens, and biological drugs, expanding choices for customizing individual treatment. However, the introduction of new drugs in the clinical setting has led to several new toxicities, creating some difficulties in daily management. Among these, ocular toxicity is generally overlooked as more common toxicities such as myelosuppression, stomatitis, diarrhea, vomiting, "hand-foot syndrome", and neurological alterations attract greater attention. Ophthalmic complications from cytotoxic chemotherapeutics are rare, transient, and of mild/moderate intensity but irreversible acute disorders are possible. The best way to prevent potential irreversible visual complications is an awareness of the potential for ocular toxicity because dose reductions or early drug cessation can prevent serious ocular complications in the majority of cases. However, given the novelty of many therapeutic agents and the complexity of ocular pathology, oncologists may be unfamiliar with these adverse effects of anticancer therapy. Although toxicities from chemotherapy are generally intense but short lasting, toxicities related to targeted drugs are often milder but longer lasting and can persist throughout treatment. Here we review the principal clinical presentations of ocular toxicity arising from chemotherapy [1-3], target therapies , and newly developed drugs and provide some recommendations for monitoring and management of ocular toxicity.
- Cancer treatment reviews.Cancer Treat Rev.2014 Feb;40(1):197-203. doi: 10.1016/j.ctrv.2013.05.005. Epub 2013 Jul 10.
- The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based chemotherapy or biological compounds depending on the disease molecular profile. In the last few years, intensive investigational efforts in anticancer thera
- PMID 23850197
- 同志社大学刑事判例研究会 昏睡状態患者の治療中止が許容されるための要件 : 川崎協同病院事件上告審決定[最高裁平成21.12.7決定]
- ... continues to convey ambiguities and lack of clarity on the legal implications of the cessation of treatment This recourse to the courts confirmed that the physician who disconnects a respirator in response to the free and ...
- Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational ... Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse ...
- cessation of treatment
- cessation of treatment
- application, care, clinical practice, cure, curing, handle, intervention, manipulate, manipulation, measure, medical care, practice, processing, remediation, remedy, therapeutic, therapeutics, therapy, transaction, treat